Introduction {#s1}
============

Alternating hemiplegia of childhood (AHC) (MIM 104290) is a rare disorder characterized by transient repeated attacks of paresis on either one or both sides of the body, occulomotor and autonomic abnormalities, movement disorders, and cognitive impairment [@pone.0056120-Bourgeois1], [@pone.0056120-Sweney1]. AHC is predominantly observed in sporadic cases without familial history, although familial AHC with autosomal dominant inheritance has also been reported [@pone.0056120-Bassi1]. Only about 50 patients with sporadic AHC have been reported in Japan and the estimated prevalence of AHC is one in a million births [@pone.0056120-Neville1].

Since the clinical features of AHC share similarity with those of familial hemiplegic migraine (FHM), previous studies applied mutational analyses of *CACNA1A* (NM_000068) and *ATP1A2* (MN_000702), which are responsible for two types of FHM, FHM1 (MIM 601011) [@pone.0056120-Ducros1] and FHM2 (MIM 182340) [@pone.0056120-DeFusco1], [@pone.0056120-Vanmolkot1], respectively, to explore the genetic cause of AHC. Although T378N, a mutation of *ATP1A2*, was identified in four affected members of a Greek family with familial AHC [@pone.0056120-Bassi1], mutations of *ATP1A2* have neither been observed in other familial cases nor in sporadic cases of AHC. Thus, candidate gene approaches have been unsuccessful in identifying the molecular pathogenic mechanism of AHC.

To elucidate the molecular basis of AHC, we hypothesized that sporadic AHC is caused by *de novo* mutations among novel non-synonymous coding variants, which are shared in patients with AHC. To test this hypothesis, we built a *de nov*o mutation detection pipeline using the exome sequencing method ([Figure 1](#pone-0056120-g001){ref-type="fig"}). Using this technique, we found that *de novo* mutations of *ATP1A3* (NM_152296) cause sporadic AHC.

![Pipeline for detection of novel *de nov*o mutations.\
The pipeline was used to identify pathogenic mutations of alternating hemiplegia of childhood (AHC). All genetic variants detected by exome sequencing are sequentially filtered through the pipeline. First, variations are screened according to databases of registered single nucleotide polymorphisms (SNP) and only non-registered SNP undergo the next selection as "Novel variants". In the next step, non-synonymous novel variants of genes expressed in the central nervous system are selected. When variations of the same gene are found in the patient, the impact of such variation is evaluated *in silico* using Grantham score and PolyPhen-2. Mutations identified at this stage are reconfirmed by Sanger sequence. *De novo* mutation is validated by analyzing samples from parents. Mutations considered pathogenic are sought in other patients with AHC if necessary.](pone.0056120.g001){#pone-0056120-g001}

Results {#s2}
=======

A total of 712,558 genetic single nucleotide variations (SNVs) and 141,933 small indels were found, including previously known and synonymous genomic variations ([Table 1](#pone-0056120-t001){ref-type="table"}). The ratios of non-overlapping variations in these patients are comparable to those of Asian or Japanese populations ([Figure S1](#pone.0056120.s001){ref-type="supplementary-material"}). The candidate variants were selected in the following processes based on the pipeline designed in the present study ([Figure 1](#pone-0056120-g001){ref-type="fig"}).

10.1371/journal.pone.0056120.t001

###### Distribution of novel non-synonymous single nucleotide polymorphisms including brain-expressed genes in eight patients with AHC.

![](pone.0056120.t001){#pone-0056120-t001-1}

  Patient ID     Total    Novel                                  
  ------------ --------- -------- -------- ------- ------- ----- -----
  I-1           229,647   5,590    6,195     282     270    77    75
  II-1          200,443   5,656    5,934     316     299    86    82
  III-1         125,855   5,489    4,304     342     327    100   93
  IV-1          251,550   5,701    7,568     405     376    129   118
  V-1           174,045   5,503    6,251     323     302    95    91
  VI-1          231,603   5,744    6,785     402     388    111   108
  VII-1         177,446   5,613    5,344     330     313    101   96
  VIII-1        178,175   5,608    4,767     295     282    78    77
  Total         712,558   1,3517   39,414   2,449   2,131   718   630

NS: non-synonymous variants, SS: splice-site acceptor/donor variants.

To select variants as candidate mutations for AHC, variations that are registered in the genomic variation databases were excluded, which resulted in a total of 39,414 single nucleotide variants and 48,056 indels. The next step was designed to select non-synonymous coding variations and those affecting splice sites, which resulted in the identification of 2,449 variations in 2,131 genes and 246 indels in 232 genes.

We then selected variations in genes expressed in the central nervous system (CNS) (Note S1) [@pone.0056120-Kang1]. Using this filter, we further narrowed the list to 718 non-synonymous SNVs and 76 indels ([Table 1](#pone-0056120-t001){ref-type="table"}). We then identified variations that were frequently shared among the 8 patients with sporadic AHC. We found that six patients (II-1, III-1, IV-1, VI-1, VII-1, and VIII-1) carried a common variant (c.2813T\>G: V938G) of *CNTN4*, four patients carried heterozygous variants of *SYNE1* (c.3955G\>A: E1319K in VII-1, c.7196T\>G: V2399A in III-1, c.10126A\>G: M3376V in V-1, and c.24665G\>A: R8222Q in I-1) and five patients carried heterozygous variants (c.2263G\>T: G755C, c.2443G\>A: E815K, and c.2780G\>A: C927Y) of *ATP1A3* ([Table 2](#pone-0056120-t002){ref-type="table"}). These variations were then subjected to validation by Sanger sequencing. The SNV of c.2813T\>G of *CNTN4* was not confirmed by Sanger sequencing, indicating that it is an error of exome sequencing.

10.1371/journal.pone.0056120.t002

###### *ATP1A3* variants found in eight individuals with AHC.

![](pone.0056120.t002){#pone-0056120-t002-2}

  Patient    Chromosome (position)   Exon        SNV                  Amino acid change
  --------- ----------------------- ------ --------------- ----------------------------------------
  I-1            19 (42479781)        16    c\. 2263 G\>T                   G755C
  II-1           19 (42474436)        18    c\. 2443 G\>A                   E815K
  III-1          19 (42474436)        18    c\. 2443 G\>A                   E815K
  IV-1           19 (42474436)        18    c\. 2443 G\>A                   E815K
  V-1            19 (42472976)        20    c\. 2780 G\>A                   C927Y
  VI-1           19 (42474557)        17    c\. 2401 G\>A   [\*](#nt103){ref-type="table-fn"}D801N
  VII-1          19 (42474557)        17    c\. 2401 G\>A   [\*](#nt103){ref-type="table-fn"}D801N
  VIII-1         19 (42474557)        17    c\. 2401 G\>A   [\*](#nt103){ref-type="table-fn"}D801N

SNV: single nucleotide variation,

D801N was initially not considered a novel mutation but confirmed later by re-analysis.

We then sought all non-synonymous coding variants of *SYNE1* in all variants identified by exome sequencing regardless of whether they were novel or had been reported previously. A total of 19 non-synonymous coding SNVs (10 in I-1, 10 in II-1, 8 in III-1, 10 in IV-1, 9 in V-1, 8 in VI-1, 10 in VII-1, and 9 in VIII-1) were found in 8 patients. Sanger sequencing was performed to search for the 4 novel variants, which were found in the 4 patients, in 96 controls and parents of the 4 patients. Among the novel variants, E1319K, V2399A and M3376V of *SYNE1* were found in 2, 2 and 2 individuals of the 96 controls, respectively. R8222Q was not found in the control. However, each of the 4 variants including R8222Q was inherited from one of the healthy parents of the probands. Taken together, these results suggest that *SYNE1* is unlikely to be the gene responsible for AHC.

Three heterozygous variants (c.2263G\>T: G755C, c.2443G\>A: E815K, and c.2780G\>A: C927Y) of *ATP1A3* were found in 5 of the 8 patients ([Table 2](#pone-0056120-t002){ref-type="table"}). We then reviewed the data of exome analysis, with a special focus on *ATP1A3*, and found another variant (c.2401G\>A: D801N) in the other 3 patients. The D801N was not initially classified as a novel variant through our pipeline, since a variant involving D801 had already been registered (though the mutation was D801Y). The D801Y mutation was reported to cause rapid-onset dystonia-parkinsonism (RDP/DYT12) (MIM 128235) [@pone.0056120-deCarvalhoAguiar1].

Sanger sequencing of *ATP1A3* confirmed four heterozygous mutations; D801N mutation in Patients I-1, VI-1 and VII-1, G755C mutation in Patient II-1, E815K in Patients III-1, IV-1 and V-1, and C927Y mutation in Patient VIII-1 ([Figure 2](#pone-0056120-g002){ref-type="fig"}). None of the variants were detected in the parents of each patient, indicating that these mutations were *de novo*. None of these variants was detected in any of the 96 healthy subjects.

![Chromatograms of four *de novo* mutations identified in *ATP1A3*.\
Data were obtained by Sanger sequencing during the confirmation process. In trio of each pedigree, black shadow represents the proband. In the chromatograms, *Black letters* show exonic nucleotide sequences, *gray letters* show intronic nucleotide sequences. Amino acids are shown in a single letter notation. Nucleotides and amino acids in red indicate mutations. (A) G755C was identified only in Patient I-1. (B) E815K was identified in Patients II-1, III-1, IV-1, IX-1 and X-1. (C) C927Y was identified in Patient V-1 only. (D) D801N was identified in Patients VI-1, VII-1 and VIII-1. None of the mutations was detected in the father or mother except for Patient IX-1, whose parents refused to undergo genetic analysis.](pone.0056120.g002){#pone-0056120-g002}

Sanger sequence analysis for *ATP1A3* was further conducted in two other unrelated individuals with sporadic AHC (Patients IX-1 and X-1, [Table 3](#pone-0056120-t003){ref-type="table"}). The analysis identified a heterozygous E815K in both patients while neither of the parents of these two patients had the mutation, confirming that the mutation was also *de novo*. These findings in the two patients provided compelling evidence for the pathogenic role of *ATP1A3* mutation in sporadic AHC. Taken together, we identified a total of four *ATP1A3* mutations in the 10 patients studied and these *de novo* mutations were considered pathogenic mutations involved in the etiology of AHC.

10.1371/journal.pone.0056120.t003

###### Clinical data of 10 unrelated individuals with AHC.

![](pone.0056120.t003){#pone-0056120-t003-3}

  Patient ID                                                                                           I-1                                                                                                                           II-1                                                                                                              III-1                                                                    IV-1                                                   V-1                                                       VI-1                                                 VII-1                                                                                 VIII-1                                                                                                                             IX-1                                                                                                               X-1
  ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------------------------------------ ------------------------------------------- ------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Age (year)/sex                                                                                     18/male                                                                                                                        13/male                                                                                                          32/female                                                                 6/male                                               16/female                                                   17/male                                              9/male                                                                                 12/male                                                                                                                           9/male                                                                                                             1/male
  Age at onset (day)                                                                                   60                                                                                                                             17                                                                                                                 2                                                                       1                                                      60                                                         1                                                   120                                                                                     0                                                                                                                              Infant                                                                                                            Neonatal
  Age at onset of paralysis (month)                                                                     6                                                                                                                             10                                                                                                                12                                                                       4                                                      12                                                         4                                                    9                                                                                      9                                                                                                                              Infant                                                                                                               9
  Initial symptoms/signs                                              L versive movement of neck, monocular deviation of L eye to the left                                                                                        Tonic fits                                                                                                        Tonic fits                                                        Upward gaze, tonic fits                          Nystagmus, ocular deviation to right                         Nystagmus, focal clonic seizure                              Clonic seizure                                                                            Nystagmus                                                                                                                          Apnea                                                                                               Nystagmus, downward gaze, tonic fits
  Paralytic type                                                                                     Flaccid                                                                                                                        Flaccid                                                                                                           Flaccid                                                                 Flaccid                                                 Rigid                                                     Flaccid                                              Flaccid                                                                                Flaccid                                                                                                                          Flaccid                                                                                                            Flaccid
  Paralytic symptoms                   Paralysis of unilateral arm or leg on R or L, or hemiparesis, sometimes continues with shift to opposite side. Rarely quadriplegia.   Paralysis of unilateral arm or leg on R or L, or hemiparesis, sometimes shifts to opposite side. Rarely quadriplegia.   Hemiparesis. Sometimes quadriplegia. No episodic paralysis since stabilizing of quadriplegia at 14 years.   Paralysis or hemiparesis of R arm.   Rigidity of R arm. Alternating flaccid hemiplegia since 1 year of age.   Alternating hemiparesis every 2--3 months   Alternating hemiplegia (R\>L), only a few days every month.   R or L unilateral arm or leg paralysis, sometimes systemic paralysis. Tendency to occur following tonic fits.   Quadriplegia with/without bulbar palsy, for a few min to several hrs every day. Sometimes hemiplegia. Sometimes paralysis shifts to other parts.   Exterior ocular deviation on R side. Systemic cataplexy. Alternating paraparesis
  Other neurological abnormalities                                                          Choreoathetosis, aphonia                                                                                                  Choreoathetosis, facial dyskinesia                                                                                Dystonia, oral or facial dyskinesia                                                   Aphonia                                            Spastic diplegia                                                None                                           Left hemidystonia                                                                          Dystonia                                                                                                                          Dystonia                                                                                            Head lag, nystagmus, ocular deviation
  Motor development                                                                                walks alone                                                                                                                stands with support                                                                                               walks with support                                                           sits alone                                            walks alone                                                walks alone                                          walks alone                                                                        walks with support                                                                                                                  Unable to sit                                                                                                       rolling over
  Intellectual development                                                                          two words                                                                                                                     only words                                                                                                        only words                                                                no words                                                Normal                                                 three phrases                                     three word phrases                                                                         only words                                                                                                                         No words                                                                                                            delay
  Regression                                                                                           No                                                                                                                             Yes                                                                                                               Yes                                                                      No                                                    Yes                                                        No                                                   No                                                                                     Yes                                                                                                                              Yes                                                                                                                 No
  Epilepsy                                                                                           4 years                                                                                                                        2 years                                                                                                           4 years                                                                   None                                                   None                                                      None                                                4months                                                                                8 years                                                                                                                            Yes                                                                                                              9months
  Epileptic status                                                                                     No                                                                                                                             Yes                                                                                                               Yes                                                                      No                                                     No                                                        No                                                   No                                                                                     Yes                                                                                                                              Yes                                                                                                                Yes
  Headache                                                                                             Yes                                                                                                                            Yes                                                                                                               No                                                                       No                                                     No                                                        No                                                   No                                                                                     No                                                                                                                             unknown                                                                                                            unknown
  Head MRI                                                                                           Normal                                                                                                                   Cerebellar atrophy                                                                                                Cerebellar atrophy                                                             Normal                             Mild enlargement of inferior horns bilaterally                                Normal                                               Normal                                                                      High intensity in hippocampus                                                                                                                 N/A                                                                                                               Normal
  Respiratory status                                                                                  Apnea                                                                                                                         Normal                                                                                                       Use of ventilator                                                             Apnea                                                  Normal                                                    Normal                                               Normal                                                                                  Apnea                                                                                                                            Apnea                                                                                                              Apnea
  Effective drugs for paralysis                                                                    flunarizine                                                                                                                        CZP                                                                                                        CZP, flunarizine                                                           flunarizine                                                CZP                                                    flunarizine                                          flunarizine                                                                            flunarizine                                                                                                              none (flunarizine not tried)                                                                                                   MDL
  Family history                                                                                      None                                                                                                                           None                                                                                                              None                                                              Headache, epilepsy                                            None                                                      None                                               Migraine                                                                          Headache, epilepsy                                                                                                                     Headache                                                                                                             None
  Gestational age                                                                                   40 weeks                                                                                                                    34 weeks 3days                                                                                                       42 weeks                                                                 40 weeks                                               unknown                                                41 weeks 4 days                                      39 weeks 3 days                                                                           41 weeks                                                                                                                          40 weeks                                                                                                       37 weeks 3 days
  Birth weight (g)                                                                                    3148                                                                                                                           2218                                                                                                              3260                                                                     3392                                                 unknown                                                     3526                                                 3200                                                                                   3008                                                                                                                              3550                                                                                                               2962
  Asphyxia                                                                                            None                                                                                                                No crying unless stimulated                                                                                                 Unknown                                                                   None                                                 unknown                                                     None                                                unknown                                                                                 None                                                                                                                              None                                                                                                               None

MDL: midazolam, CZP: clonazepam, L: left, R: right.

The clinical features of AHC patients with *de novo* mutations are summarized in [Table 3](#pone-0056120-t003){ref-type="table"}. Four of the 5 patients with E815K and 1 of the 3 patients with D801N had respiratory abnormalities such as apnea, and one of the patients with E815K required mechanical ventilation. Furthermore, patients with E815K and D801N suffered from status epilepticus, and various involuntary movements were encountered in those harboring E815K mutation. Unfortunately, the small number of patients in our study precluded any firm conclusions backed by proper statistical analysis between genotype and phenotype. However, the results suggested the frequent presence of severe neurological complications, such as aphonia, choreoathetosis, dyskinesia and epilepsy, in individuals with E815K ([Table 3](#pone-0056120-t003){ref-type="table"}). The attending physicians also provided answers to our survey on medications that were considered effective in the control of paralysis ([Table 3](#pone-0056120-t003){ref-type="table"}).

Discussion {#s3}
==========

By applying the exome sequencing strategy, we have demonstrated in the present study that *de novo ATP1A3* mutations cause sporadic AHC. Our work provides evidence that *ATP1A3* is the responsible gene for sporadic AHC, a rare but devastating disease that lacks proper treatment so far. At the time of the writing of this communication, two independent research groups, one from the USA and the other from Germany [@pone.0056120-Heinzen1], [@pone.0056120-Rosewich1], reported similar findings. Collectively, the three studies confirm that *ATP1A3* is the causative gene for AHC.

*ATP1A3* is a member of the gene family that encodes the alpha subunits of Na^+^/K^+^ transporting ATPase, which regulates the electrochemical gradients of Na^+^ and K^+^ through active transport. These ions are essential for regulation of cellular osmolality and the action potentials of excitable membrane. *ATP1A1*, *ATP1A2* and *ATP1A3* encode alpha 1, 2 and 3 subunits, respectively, which are mainly expressed in interneurons and pyramidal cells[@pone.0056120-McGrail1], suggesting that they play important roles in the brain.

A total of 25 mutations identified to date reside in or near transmembrane domains ([Figure 3](#pone-0056120-g003){ref-type="fig"}). The G755C and E815K are at the cytoplasmic domain. However, E815K resides more in the transmembrane domain than in the cytoplasmic domain. The D801N and C927Y are at the transmembrane domains, M6 and M8, respectively, and form a helical structure. Also, C927Y identified in our study is a novel mutation.

![*ATP1A3* mutations and their protein domain structures.\
*Black lined circle:* Mutations reported recently [@pone.0056120-Heinzen1], [@pone.0056120-Rosewich1]. *Red colored circle:* Mutations identified in the present study in a Japanese cohort with AHC. The *ATP1A3* gene consists of 23 exons that encode several domains in the ATP1A3 protein molecule, including 6 cytoplasmic, 10 helical and 5 extracellular domains. G755C and E815K were located in the cytoplasmic domains. Notably, E815K was resident of the transmembrane domain rather than the cytoplasmic domain. D801N and C927Y were located in the helical domains. C927Y was identified in this study only and hence considered novel.](pone.0056120.g003){#pone-0056120-g003}

The amino acids substituted in each mutation are highly conserved among Na^+^/K^+^ ATPase isoforms of various species ([Figure 4](#pone-0056120-g004){ref-type="fig"}), suggesting that the amino acids are crucial for ATPase function. In fact, *in silico* analysis of the mutations identified in the present study suggests a profound damage of the ATPase molecule and hence accord well with functional deficits of the ATPase encountered with the recently described mutations [@pone.0056120-Heinzen1].

![Homologous comparison of altering-protein.\
*Blue letters:* altering-protein by mutation, *red letters:* differential protein with human. (A) G755C changed by novel SNVs (c.2263G\>T) of *ATP1A3* in Patient I-1. (B) E815K changed by novel SNVs (c.2443 G\>A) of *ATP1A3* in Patients II-1, III-1, IV-1, IX-1 and X-1. (C) C927Y changed by novel SNVs (c.2780 G\>A) of *ATP1A3* in Patient V-1. (D) D801N changed by novel SNVs (c.2401 G\>A) of *ATP1A3* in Patient VI-1, VII-1 and VIII-1.](pone.0056120.g004){#pone-0056120-g004}

It is noteworthy that several mutations of *ATP1A3* have been reported to cause RDP [@pone.0056120-deCarvalhoAguiar1]. RDP is an autosomal dominant disease characterized by abrupt onset of dystonia and Parkinsonism, developing within minutes to days of onset [@pone.0056120-Brashear1]--[@pone.0056120-Pittock1]. Recently reported were two infantile RDP patients with *ATP1A3* mutations (R756H and D923N); onset began for one of them at 11 months and for the other at 4 years of age. Major symptoms included motor delay, hypotonia, and ataxia [@pone.0056120-Anselm1], [@pone.0056120-Brashear2]. Involuntary movements such as dystonia overlap with AHC, however, their clinical features and age of onset are different than those of AHC, which mainly shows repeated attacks of alternating hemiplegia and which begins with abnormal ocular movements by 3 months of age. Both typical and infantile RDP show different clinical features and processes than AHC, although *ATP1A3* seems to be pathologically involved in both disorders. In particular, D801N, one of the *ATP1A3* mutations identified in the present study, affected D801, where D801Y had been found in RDP. Thus, it seems that two substitutions in the same amino acid result in two distinguished phenotypes. Initially, we could not identify D801N in *ATP1A3* from novel variant. The reason for the erroneous results was the extraction of novel variants from all the variants using chromosome position only during the collation of databases. The position 42474557 of chromosome 19, where the G to A transversion resulted in D801N identified by our exome sequencing, had been registered as the nucleotide where the G to T transition is identified in rapid-onset dystonia-parkinsonism. Based on the backup plans involving reconfirmation of the gene identified with novel variants, using all variants, and to re-sequence the gene in our pipeline with the Sanger sequencer, D801N was not overlooked in the present study. These results suggest that confirmation by Sanger sequencer is useful in avoiding any oversight in the field of gene identification.

Functional analysis of *ATP1A3* mutations in RDP by haplo-insufficiency demonstrated low protein levels of the corresponding ATPase [@pone.0056120-deCarvalhoAguiar1]. In addition, Heinzen *et al.* demonstrated that none of the mutations causes AHC reduced protein levels, whereas both mutations of AHC and those of RDP reduced ATPase activity [@pone.0056120-Heinzen1]. These studies suggested that mutations identified in AHC affect the Na^+^/K^+^ ATPase pump function due to inhibition of ion binding. This implies that D801N substitutions can cause pump dysfunction more than D801Y. Heterozygous knock-out mice and knock-in mice deficient in *ATP1A3* have been generated. The *ATP1A3* knock-out mice were found to have reduced NMDA receptors and exhibited neurological abnormalities such as hyperactivity, spatial learning and memory deficit [@pone.0056120-Moseley1]. The mice harboring mutation I810N of *ATP1A3*, which were neither RPD nor AHC, developed seizures [@pone.0056120-Clapcote1]. While these phenotypes do not necessarily correspond with the typical clinical manifestations observed in either RDP or AHC, some similarities do exist.

In total, we identified four *ATP1A3* mutations in 10 Japanese AHC patients. All were heterozygous and *de novo*. Although the number of patients was small (10 individuals), E815K and D801N were observed in 5 (50%) and 3 (30%) of the 10 patients, respectively.

The exact mechanism of *de novo* mutation identified in this study is not clear at present. The nucleotides of both E815K and D801N are located in the GC-rich sequences of *ATP1A3*, and within 6-bp palindrome. These features may be related to the development of these *de novo* mutations.

Intriguingly, E815K mutation of *ATP1A3* found in half of our patients was associated with the presence of severe neurological symptoms, respiratory failure, status epilepticus and resistance to medications. The attending physicians consider, with hindsight clinical experience that flunarizine seems to be less effective in individuals with E815K mutation, compared to those with other mutations. However, the association between genotype and phenotype remains undefined due to the small number of the cohort. The present findings and those of other groups on AHC associated with *ATP1A3* mutations warrant further studies to understand the relation between genotype and phenotype in AHC and to develop new tools for the diagnosis and treatment of AHC.

Patients and Methods {#s4}
====================

Ethics statement {#s4a}
----------------

The present study was approved by the Ethics Review Committees of Fukuoka University and the University of Tokyo. Parents of each patient and the parents themselves provided signed informed consent before the study.

Patients {#s4b}
--------

We initially recruited 10 unrelated Japanese individuals with clinical features of typical sporadic AHC. The diagnosis of AHC was based on the criteria of AHC [@pone.0056120-Bourgeois1], [@pone.0056120-Sweney1]. The clinical presentations of these patients were typical but the neurological symptoms showed some variations, including aphonia, choreoathetosis, dyskinesia, epilepsy, and episodic apnea. Furthermore, variability in the response to different medications, such as flunarizine, was also noted among the patients ([Table 3](#pone-0056120-t003){ref-type="table"}). Flunarizine was used for the treatment of 9 patients to control paralysis. The frequency of the paretic symptom decreased somewhat following the treatment, compared to that with other medications. However, the response to treatment, as evaluated subjectively by the attending physician, was not remarkable. Two patients (II-1 and V-1) showed a better response to clonazepam than to flunarizine.

The patients studied were 8 males and 2 females with similar clinical presentation, including infantile onset and psychomotor retardation. MRI images showed high-intensity hippocampal region in patient VIII-1 ([Table 3](#pone-0056120-t003){ref-type="table"}), which was considered secondary to repeated episodes of epileptic convulsions. MRI images in patients II-1 and III-1 showed cerebellar atrophy, which was considered a primary lesion similar to FHM. The MRI findings in patient V-1 were considered non-specific.

Based on the availability of samples from the parents of the 9 patients, we selected 8 probands (subjects I-1 to VIII-1, [Table 3](#pone-0056120-t003){ref-type="table"}) for exome sequencing analysis. After the identification of *de novo* heterozygous mutations in 8 patients, we also collected samples from the parents of patient IX-1 and also samples from patient X-1 and his parents. Parents of the patients with available genomic DNAs were also enrolled in this study. We also recruited 96 unrelated healthy Japanese volunteers as the control group who were free of seizures or history of epilepsy.

Genomic DNA was prepared from EDTA-Na~2~-containing blood samples using the QIAamp DNA Blood Maxi Kit (Qiagen, Hilden, Germany), using the protocol provided by the manufacturer.

Exome sequencing {#s4c}
----------------

The exonic sequences were enriched using the Agilent SureSelect technology for targeted exon capture (213,383 exons, covering approximately 50 Mb of the CCDS database) (Agilent Technologies, Santa Clara, CA) from 3 µg of genomic DNA, using the protocol provided by the manufacturer. The captured DNAs were subjected to massively parallel sequencing (100 bp paired-end reads) on the Illumina Hiseq2000 (Illumina, San Diego, CA). The average of 1.3 billion bases of the sequence data was obtained for each individual. On average, 99.08% of the total bases were mapped to the reference genome with a mean coverage of 182.8x, which encompassed 92.99% of the targeted regions with coverage \>10x. Burrows Wheeler Aligner [@pone.0056120-Li1] and Samtools [@pone.0056120-Li2] were used as default settings for alignment of raw reads and detection of variations. The variants were filtered against dbSNP (build 135). The aligned short reads were viewed using the University of Tokyo Genome Browser (UTGB) [@pone.0056120-Saito1].

Sanger sequencing {#s4d}
-----------------

Sanger sequencing was performed to validate the presence of each variant detected by exome sequencing in patients with AHC and the absence of each in the parental genomes. The entire exons and the intron-exon boundaries of *ATP1A3*, *CNTN4* (NM_175607) and *SYNE1* (NM_033071) were amplified by PCR using the designed PCR primers ([Table S1](#pone.0056120.s003){ref-type="supplementary-material"} lists the primer sequences and the PCR conditions). The PCR products were purified in ExoSAP-IT for PCR Product Clean-Up (Affymetrix, Santa Clara, CA) set at one cycle of 15 min at 37°C and 15 min at 80°C. The purified PCR products were sequenced using the ABI PRISM BigDye 3.1 terminator method (Applied Biosystems, Foster City, CA) and the ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems).

URLs {#s4e}
----

BLAST: <http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome> Japanese Society of Alternating hemiplegia of childhood: <http://www008.upp.so-net.ne.jp/ahc/>

Accession numbers {#s4f}
-----------------

Reference sequences are available from NCBI under the following accession codes: *CACNA1A:*NM_000068

*ATP1A2*:MN_000702

*CNTN4:* NM_175607

*ATP1A3:* NM_152296

*SYNE1:* NM_033071
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**Rations of single nucleotide variations (SNVs) overlapping with known polymorphisms in various ethnic backgrounds.**

(DOC)

###### 

Click here for additional data file.

###### 

**Brain-expressed genes.**

(DOC)

###### 

Click here for additional data file.

###### 

**PCR primers and conditions designed for** ***ATP1A3*** **.**

(DOC)

###### 

Click here for additional data file.
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